

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UM-04594	Serial No.: 09/651,685									
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets if Necessary)				Applicant: Peter A. Ward <i>et al.</i>										
(37 CFR § 1.98(b))				Filing Date: 08/30/00		Group Art Unit: 1644-1644								
U.S. PATENT DOCUMENTS														
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date							
PV	1	4,357,272	11/02/82	Polson	260	142 R	3/15/79							
	2	5,051,448	9/24/91	Shashoua	514	547	5/07/90							
	3	5,169,862	12/08/92	Burke, Jr. <i>et al.</i>	514	450	11/18/91							
	4	5,192,746	3/09/93	Lobl <i>et al.</i>	514	11	7/09/90							
	5	5,260,203	1/09/93	Ladner <i>et al.</i>	435	172.3	4/25/90							
	6	5,340,923	8/23/94	Carroll	530	389.1	11/17/92							
	7	5,539,085	7/23/96	Bischoff <i>et al.</i>	530	350	8/20/93							
	8	5,559,103	9/24/96	Gaeta <i>et al.</i>	514	54	7/20/94							
	9	5,565,332	10/15/96	Hoogenboom <i>et al.</i>	435	69.1	9/23/92							
	10	5,576,423	11/19/96	Aversa <i>et al.</i>	530	388.75	12/02/94							
	11	5,585,089	12/17/96	Queen <i>et al.</i>	424	133.1	6/07/95							
	12	5,658,727	8/19/97	Barbas <i>et al.</i>	435	6	4/10/92							
	13	5,904,922	5/18/99	Carroll	424	130.1	5/16/95							
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS														
PV		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation							
							Yes	No						
							14	EP 0025949 B1	01.04.81	EPO ENGLISH CLAIMS ONLY				
							15	WO 96/39503	12.12.96	PCT				
16	EP 0245993 A2	19.11.87	EPO											
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)														
PV	17	Ames RS <i>et al.</i> , "Isolation of Neutralizing Anti-C5a Monoclonal Antibodies from a Filamentous Phage Monovalent Fab Display Library," <i>J Immunol</i> 152:4572-4581 (1994)												
	18	R.C. Bone, "The Pathogenesis of Sepsis," <i>Ann. Intern. Med.</i> 115:457-469 (1991)												
PV	19	E.S. Caplan and N. Hoyt, "Infection Surveillance and Control in the Severely Traumatized Patient," <i>Am. J. Med.</i> 70:638-640 (1981)												
	20	Caruthers <i>et al.</i> , "New chemical methods for synthesizing polynucleotides," <i>Nuc. Acids Res. Symp. Ser.</i> 7:215-233 (1980)												
PV	21	Chow and Kempe, "Synthesis of oligodeoxyribonucleotides on silica gel support," <i>Nuc. Acids Res.</i> 9:2807-2817 (1981)												
	22	Crea and Horn, "Synthesis of oligonucleotides on cellulose by a phosphotriester method," <i>Nuc. Acids Res.</i> 9:2331 (1980)												
PV	23	Creighton (1983) <i>Proteins Structures And Molecular Principles</i> , W H Freeman and Co, New York N.Y.												
	24	Czermak BJ. <i>et al.</i> , "Protective effects of a C5a blockade in sepsis," <i>Nature Medicine</i> 5:788-792 (1999)												
PV	25	Davis <i>et al.</i> , <i>Basic Methods in Molecular Biology</i> , (1986)												
	26	Elzaim, <i>et al.</i> , "Generation of Neutralizing Antipeptide Antibodies to the Enzymatic Domain of <i>Pseudomonas aeruginosa</i> Exotoxin A," <i>Infect. Immun.</i> May;66(5):2170-9 (1998)												
PV	27	Evans <i>et al.</i> , "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies," <i>Nature</i> 339:385-388 (1989)												
	Examiner: <i>John D. Doherty</i>	Date Considered: 6/23/03												
EXAMINER: <i>John D. Doherty</i>	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-04594	Serial No.: 09/651,685																																																																																																																																												
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: Peter A. Ward <i>et al.</i>																																																																																																																																														
		Filing Date: 08/30/00	Group Art Unit: 1641 1644																																																																																																																																													
<p style="text-align: center;">MAR 27 2003</p> <p>OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)</p> <table border="1"> <tr> <td>28</td> <td colspan="4">Gerard C. <i>et al.</i>, "Amino Acid Sequence of the Anaphylatoxin from the fifth Component of Porcine Complement," <i>J. Biol. Chem.</i> 255(10). 4710-4715, (1980)</td> </tr> <tr> <td>29</td> <td colspan="4">Gluzman, "SV40-Transformed Simian Cells Support the Replication of early SV40 Mutants," <i>Cell</i>, 23:175-182 (1981)</td> </tr> <tr> <td>30</td> <td colspan="4">Hatherhill JR <i>et al.</i>, "Effects of Anti-C5a Antibodies on Human Polymorphonuclear Leukocyte Function: Chemotaxis, Chemiluminescence, and Lysosomal Enzyme Release" <i>J of Biological Response Modifiers</i> 8:614-624 (1989)</td> </tr> <tr> <td>31</td> <td colspan="4">Hill, J.H. and Ward, P.A., "The Phlogistic Role of C3 Leukotactic Fragments in Myocardial Infarcts of Rats," <i>J. Exp. Med.</i> 133:885-900 (1971)</td> </tr> <tr> <td>32</td> <td colspan="4">Hochuli <i>et al.</i>, "New Metal Chelate Adsorbent Selective for Proteins and Peptides Containing Neighbouring Histidine Residues." <i>J Chromatography</i> 411:177-184 (1987)</td> </tr> <tr> <td>33</td> <td colspan="4">A.M. Hoffman <i>et al.</i>, "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," <i>J. Vet. Int. Med.</i> 6:89-95 (1992)</td> </tr> <tr> <td>37</td> <td colspan="4">Huang <i>et al.</i>, "Vaccinia Virus Recombinants Expressing an 11-Kilodalton β-Galactosidase Fusion Protein Incorporate Active β-Galactosidase in Virus Particles," <i>J. Virol.</i> 62:3855-3861 (1988)</td> </tr> <tr> <td>35</td> <td colspan="4">W.K. Joklik <i>et al.</i> (eds.), <i>Zinsser Microbiology</i>, 18th ed., Chapter 27 <i>Streptococcus pneumoniae</i>, p. 485-489, Appleton-Century-Crofts, Norwalk, CT (1984)</td> </tr> <tr> <td>36</td> <td colspan="4">Kennet, R.H., <i>Monoclonal Antibodies, Hybridoma - A New Dimension in Biological Analysis</i>, Plenum Press, NY (1980)</td> </tr> <tr> <td>37</td> <td colspan="4">Kettleborough, <i>et al.</i>, "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> 4(7):773-783 (1991)</td> </tr> <tr> <td>38</td> <td colspan="4">Kohl, J., and Bitter-Suermann, D., <i>Anaphylatoxins. Complement in health and disease.</i>, Edited by Whaley, K., Loos, M., Weiler, J.M., Kluwer Academic publishers, pp 299-324 (1993)</td> </tr> <tr> <td>39</td> <td colspan="4">Kohler, G. and Milstein, C., <i>Continuous</i> cultures of fused cells secreting antibody of predined specificity," <i>Nature</i> 256:495-497 (1975) <i>6/23/03</i></td> </tr> <tr> <td>40</td> <td colspan="4">Kola <i>et al.</i>, "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis". <i>Immunotechnology</i> 1:115-126 (1996)</td> </tr> <tr> <td>41</td> <td colspan="4">Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes," <i>Immunol. Today</i> 4:72-79 (1983)</td> </tr> <tr> <td>42</td> <td colspan="4">Larrick JW <i>et al.</i>, "Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing Epitopes on Human C5a" <i>Infection and Immunity</i> 55:1867-1872 (1987)</td> </tr> <tr> <td>43</td> <td colspan="4">G.W. Machiedo <i>et al.</i>, "Patterns of Mortality in a Surgical Intensive Care Unit," <i>Surg. Gyn. & Obstet.</i> 152:757-759 (1981)</td> </tr> <tr> <td>44</td> <td colspan="4">Mandecki W, <i>et al.</i>, "Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in <i>Escherichia coli</i>," <i>Proc Natl Acad Sci U S A.</i> 82(11):3543-7 (1985)</td> </tr> <tr> <td>45</td> <td colspan="4">Matteucci and Caruthers, "The Synthesis of Oligodeoxypyrimidines on a Polymer Support," <i>Tetrahedron Lett</i> 21:719-722 (1980)</td> </tr> <tr> <td>46</td> <td colspan="4">M. Meek <i>et al.</i>, "The Baltimore Sepsis Scale: Measurement of Sepsis in Patients with Burns Using a New Scoring System." <i>J. Burn Care Rehab.</i> 12:564-568 (1991)</td> </tr> <tr> <td>47</td> <td colspan="4">Mohr M. <i>et al.</i>, "Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis," <i>Eur J Clin Invest</i> 28:227-234 (1998)</td> </tr> <tr> <td>48</td> <td colspan="4">D.D. Morris <i>et al.</i>, "Endotoxemia in neonatal calves given antiserum to a mutant <i>Escherichia coli</i> (J-5)," <i>Am. J. Vet. Res.</i> 47:2554-2565 (1986)</td> </tr> <tr> <td>49</td> <td colspan="4">Mulligan, M.S. <i>et al.</i>, "Requirement and Role of C5a in Acute Lung Inflammatory Injury in Rats," <i>J. Clin. Invest.</i> 98:503-512 (1996)</td> </tr> <tr> <td>50</td> <td colspan="4">Nardelli <i>et al.</i>, "A Chemically Defined Synthetic Vaccine Model for HIV-1," <i>J. Immunol.</i> 148:914-920 (1992)</td> </tr> <tr> <td>51</td> <td colspan="4">R.L. Nichols in <i>Decision Making in Surgical Sepsis</i>, B.C. Decker, Inc., Philadelphia, "Classification of Surgical Wounds and Nonoperative Factors Influencing Surgical Wound Infection," pp. 20-21 (1991)</td> </tr> <tr> <td>52</td> <td colspan="4">Nilsson <i>et al.</i>, "Affinity Fusion Strategies for Detection, Purification, and Immobilization of Recombinant Proteins." <i>Protein Expression and Purification</i> 11:1-16 (1997)</td> </tr> <tr> <td>53</td> <td colspan="4">Olson, L.M., <i>et al.</i>, "The Role of C5 in Septic Lung Injury," <i>Ann. Surg.</i> 202:771-776 (1985)</td> </tr> <tr> <td>Examiner: <i>P. A. Ward</i></td> <td colspan="4">Date Considered: <i>6/23/03</i></td> </tr> <tr> <td>EXAMINER:</td> <td colspan="4">Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</td> </tr> </table>					28	Gerard C. <i>et al.</i> , "Amino Acid Sequence of the Anaphylatoxin from the fifth Component of Porcine Complement," <i>J. Biol. Chem.</i> 255(10). 4710-4715, (1980)				29	Gluzman, "SV40-Transformed Simian Cells Support the Replication of early SV40 Mutants," <i>Cell</i> , 23:175-182 (1981)				30	Hatherhill JR <i>et al.</i> , "Effects of Anti-C5a Antibodies on Human Polymorphonuclear Leukocyte Function: Chemotaxis, Chemiluminescence, and Lysosomal Enzyme Release" <i>J of Biological Response Modifiers</i> 8:614-624 (1989)				31	Hill, J.H. and Ward, P.A., "The Phlogistic Role of C3 Leukotactic Fragments in Myocardial Infarcts of Rats," <i>J. Exp. Med.</i> 133:885-900 (1971)				32	Hochuli <i>et al.</i> , "New Metal Chelate Adsorbent Selective for Proteins and Peptides Containing Neighbouring Histidine Residues." <i>J Chromatography</i> 411:177-184 (1987)				33	A.M. Hoffman <i>et al.</i> , "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," <i>J. Vet. Int. Med.</i> 6:89-95 (1992)				37	Huang <i>et al.</i> , "Vaccinia Virus Recombinants Expressing an 11-Kilodalton β -Galactosidase Fusion Protein Incorporate Active β -Galactosidase in Virus Particles," <i>J. Virol.</i> 62:3855-3861 (1988)				35	W.K. Joklik <i>et al.</i> (eds.), <i>Zinsser Microbiology</i> , 18th ed., Chapter 27 <i>Streptococcus pneumoniae</i> , p. 485-489, Appleton-Century-Crofts, Norwalk, CT (1984)				36	Kennet, R.H., <i>Monoclonal Antibodies, Hybridoma - A New Dimension in Biological Analysis</i> , Plenum Press, NY (1980)				37	Kettleborough, <i>et al.</i> , "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> 4(7):773-783 (1991)				38	Kohl, J., and Bitter-Suermann, D., <i>Anaphylatoxins. Complement in health and disease.</i> , Edited by Whaley, K., Loos, M., Weiler, J.M., Kluwer Academic publishers, pp 299-324 (1993)				39	Kohler, G. and Milstein, C., <i>Continuous</i> cultures of fused cells secreting antibody of predined specificity," <i>Nature</i> 256:495-497 (1975) <i>6/23/03</i>				40	Kola <i>et al.</i> , "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis". <i>Immunotechnology</i> 1:115-126 (1996)				41	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes," <i>Immunol. Today</i> 4:72-79 (1983)				42	Larrick JW <i>et al.</i> , "Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing Epitopes on Human C5a" <i>Infection and Immunity</i> 55:1867-1872 (1987)				43	G.W. Machiedo <i>et al.</i> , "Patterns of Mortality in a Surgical Intensive Care Unit," <i>Surg. Gyn. & Obstet.</i> 152:757-759 (1981)				44	Mandecki W, <i>et al.</i> , "Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in <i>Escherichia coli</i> ," <i>Proc Natl Acad Sci U S A.</i> 82(11):3543-7 (1985)				45	Matteucci and Caruthers, "The Synthesis of Oligodeoxypyrimidines on a Polymer Support," <i>Tetrahedron Lett</i> 21:719-722 (1980)				46	M. Meek <i>et al.</i> , "The Baltimore Sepsis Scale: Measurement of Sepsis in Patients with Burns Using a New Scoring System." <i>J. Burn Care Rehab.</i> 12:564-568 (1991)				47	Mohr M. <i>et al.</i> , "Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis," <i>Eur J Clin Invest</i> 28:227-234 (1998)				48	D.D. Morris <i>et al.</i> , "Endotoxemia in neonatal calves given antiserum to a mutant <i>Escherichia coli</i> (J-5)," <i>Am. J. Vet. Res.</i> 47:2554-2565 (1986)				49	Mulligan, M.S. <i>et al.</i> , "Requirement and Role of C5a in Acute Lung Inflammatory Injury in Rats," <i>J. Clin. Invest.</i> 98:503-512 (1996)				50	Nardelli <i>et al.</i> , "A Chemically Defined Synthetic Vaccine Model for HIV-1," <i>J. Immunol.</i> 148:914-920 (1992)				51	R.L. Nichols in <i>Decision Making in Surgical Sepsis</i> , B.C. Decker, Inc., Philadelphia, "Classification of Surgical Wounds and Nonoperative Factors Influencing Surgical Wound Infection," pp. 20-21 (1991)				52	Nilsson <i>et al.</i> , "Affinity Fusion Strategies for Detection, Purification, and Immobilization of Recombinant Proteins." <i>Protein Expression and Purification</i> 11:1-16 (1997)				53	Olson, L.M., <i>et al.</i> , "The Role of C5 in Septic Lung Injury," <i>Ann. Surg.</i> 202:771-776 (1985)				Examiner: <i>P. A. Ward</i>	Date Considered: <i>6/23/03</i>				EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
28	Gerard C. <i>et al.</i> , "Amino Acid Sequence of the Anaphylatoxin from the fifth Component of Porcine Complement," <i>J. Biol. Chem.</i> 255(10). 4710-4715, (1980)																																																																																																																																															
29	Gluzman, "SV40-Transformed Simian Cells Support the Replication of early SV40 Mutants," <i>Cell</i> , 23:175-182 (1981)																																																																																																																																															
30	Hatherhill JR <i>et al.</i> , "Effects of Anti-C5a Antibodies on Human Polymorphonuclear Leukocyte Function: Chemotaxis, Chemiluminescence, and Lysosomal Enzyme Release" <i>J of Biological Response Modifiers</i> 8:614-624 (1989)																																																																																																																																															
31	Hill, J.H. and Ward, P.A., "The Phlogistic Role of C3 Leukotactic Fragments in Myocardial Infarcts of Rats," <i>J. Exp. Med.</i> 133:885-900 (1971)																																																																																																																																															
32	Hochuli <i>et al.</i> , "New Metal Chelate Adsorbent Selective for Proteins and Peptides Containing Neighbouring Histidine Residues." <i>J Chromatography</i> 411:177-184 (1987)																																																																																																																																															
33	A.M. Hoffman <i>et al.</i> , "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," <i>J. Vet. Int. Med.</i> 6:89-95 (1992)																																																																																																																																															
37	Huang <i>et al.</i> , "Vaccinia Virus Recombinants Expressing an 11-Kilodalton β -Galactosidase Fusion Protein Incorporate Active β -Galactosidase in Virus Particles," <i>J. Virol.</i> 62:3855-3861 (1988)																																																																																																																																															
35	W.K. Joklik <i>et al.</i> (eds.), <i>Zinsser Microbiology</i> , 18th ed., Chapter 27 <i>Streptococcus pneumoniae</i> , p. 485-489, Appleton-Century-Crofts, Norwalk, CT (1984)																																																																																																																																															
36	Kennet, R.H., <i>Monoclonal Antibodies, Hybridoma - A New Dimension in Biological Analysis</i> , Plenum Press, NY (1980)																																																																																																																																															
37	Kettleborough, <i>et al.</i> , "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> 4(7):773-783 (1991)																																																																																																																																															
38	Kohl, J., and Bitter-Suermann, D., <i>Anaphylatoxins. Complement in health and disease.</i> , Edited by Whaley, K., Loos, M., Weiler, J.M., Kluwer Academic publishers, pp 299-324 (1993)																																																																																																																																															
39	Kohler, G. and Milstein, C., <i>Continuous</i> cultures of fused cells secreting antibody of predined specificity," <i>Nature</i> 256:495-497 (1975) <i>6/23/03</i>																																																																																																																																															
40	Kola <i>et al.</i> , "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis". <i>Immunotechnology</i> 1:115-126 (1996)																																																																																																																																															
41	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes," <i>Immunol. Today</i> 4:72-79 (1983)																																																																																																																																															
42	Larrick JW <i>et al.</i> , "Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing Epitopes on Human C5a" <i>Infection and Immunity</i> 55:1867-1872 (1987)																																																																																																																																															
43	G.W. Machiedo <i>et al.</i> , "Patterns of Mortality in a Surgical Intensive Care Unit," <i>Surg. Gyn. & Obstet.</i> 152:757-759 (1981)																																																																																																																																															
44	Mandecki W, <i>et al.</i> , "Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in <i>Escherichia coli</i> ," <i>Proc Natl Acad Sci U S A.</i> 82(11):3543-7 (1985)																																																																																																																																															
45	Matteucci and Caruthers, "The Synthesis of Oligodeoxypyrimidines on a Polymer Support," <i>Tetrahedron Lett</i> 21:719-722 (1980)																																																																																																																																															
46	M. Meek <i>et al.</i> , "The Baltimore Sepsis Scale: Measurement of Sepsis in Patients with Burns Using a New Scoring System." <i>J. Burn Care Rehab.</i> 12:564-568 (1991)																																																																																																																																															
47	Mohr M. <i>et al.</i> , "Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis," <i>Eur J Clin Invest</i> 28:227-234 (1998)																																																																																																																																															
48	D.D. Morris <i>et al.</i> , "Endotoxemia in neonatal calves given antiserum to a mutant <i>Escherichia coli</i> (J-5)," <i>Am. J. Vet. Res.</i> 47:2554-2565 (1986)																																																																																																																																															
49	Mulligan, M.S. <i>et al.</i> , "Requirement and Role of C5a in Acute Lung Inflammatory Injury in Rats," <i>J. Clin. Invest.</i> 98:503-512 (1996)																																																																																																																																															
50	Nardelli <i>et al.</i> , "A Chemically Defined Synthetic Vaccine Model for HIV-1," <i>J. Immunol.</i> 148:914-920 (1992)																																																																																																																																															
51	R.L. Nichols in <i>Decision Making in Surgical Sepsis</i> , B.C. Decker, Inc., Philadelphia, "Classification of Surgical Wounds and Nonoperative Factors Influencing Surgical Wound Infection," pp. 20-21 (1991)																																																																																																																																															
52	Nilsson <i>et al.</i> , "Affinity Fusion Strategies for Detection, Purification, and Immobilization of Recombinant Proteins." <i>Protein Expression and Purification</i> 11:1-16 (1997)																																																																																																																																															
53	Olson, L.M., <i>et al.</i> , "The Role of C5 in Septic Lung Injury," <i>Ann. Surg.</i> 202:771-776 (1985)																																																																																																																																															
Examiner: <i>P. A. Ward</i>	Date Considered: <i>6/23/03</i>																																																																																																																																															
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																																																																																																																																															

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UM-04594	Serial No.: 09/651,685
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: Peter A. Ward <i>et al.</i>		
		Filing Date: 08/30/00		Group Art Unit: 1641 1644
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
54	MAR 27 2003 RECEIVED U.S. PATENT AND TRADEMARK OFFICE Hank KW. <i>et al.</i> , "Attenuation of Endothelium-Dependent Dilatation of Pig Pulmonary Arterioles After Cardiopulmonary Bypass Is Prevented by Monoclonal Antibody to Complement C5a," <i>Anesth Analg</i> 89:42-48 (1999)			
55	Posnett <i>et al.</i> , "A Novel Method for Producing Anti-peptide Antibodies," <i>JBC</i> 263:1719-1725 (1988)			
56	Protein Accession Number A57689/ GI "2118416"			
57	Protein Accession Number P01032/ GI "116605"			
58	Protein Accession Number P12082/ GI "116604"			
59	Roberge <i>et al.</i> , "A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support," <i>Science</i> 269:202-204 (1995)			
60	Rothermel <i>et al.</i> , Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a," <i>Biochim. Biophys. Acta</i> 1351:9-12, (1997)			
61	Schlienger <i>et al.</i> , "Human Immunodeficiency Virus Type I Major Neutralizing Determinant Exposed on Hepatitis B Surface Antigen Particles is Highly Immunogenic in Primates," <i>J. Virol.</i> 66:2570-2576 (1992)			
62	K.A. Schulman <i>et al.</i> , "Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis," <i>JAMA</i> 266:3466-3471 (1991)			
63	J.M. Slack and I.S. Snyder, <i>Bacteria and Human Disease</i> , pp. 128-133, Yearbook Medical Publishers (1978)			
64	Solomkin, <i>et al.</i> , "Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation," <i>Surgery</i> 90:319-327, (1981)			
65	Stahel, <i>et al.</i> , "TNF- α -Mediated Expression of the Receptor for Anaphylatoxin C5a on Neurons in Experimental Listeria Meningoencephalitis," <i>J. Immunol.</i> 159(2):861-9 (1997)			
66	Stevens JH. <i>et al.</i> , "Effects of Anti-C5a Antibodies on the Adult Respiratory Distress Syndrome in Septic Primates," <i>J Clin Invest</i> 77:1812-1816 (1986)			
67	<i>Glyer ed., Biochemistry, 2nd ed., WH Freeman and Co. (1981)</i>			
68	Van Epps, <i>et al.</i> , "Relationship of C5a Receptor Modulation to the Functional Responsiveness of Human Polymorphonuclear Leukocytes to C5a," <i>J. Immunol.</i> 150:246-252 (1993)			
69	Ward, P.A. & Becker, E.L., "The Deactivation of Rabbit Neutrophils by Chemotactic Factor and the Nature of the Activatable Esterase," <i>J. Exp. Med.</i> 127:693-709 (1968)			
70	Wilson, <i>et al.</i> , "The Structure of an Antigenic Determinant in a Protein," <i>Cell</i> 37:767-778 (1984)			
71	S.M. Wolff, "Monoclonal Antibodies and the Treatment of Gram-Negative Bacteremia and Shock," <i>New Eng. J. Med.</i> 324:486-488 (1991)			
72	G.P. Youmans <i>et al.</i> , <i>Biologic and Clinical Basis of Infectious Diseases</i> , 3d ed., "Central Nervous System Infection: General Consideration," pp. 552-568, W.B. Saunders Co., (1985)			
73	Zarbock, J., <i>et al.</i> , "A proton nuclear magnetic resonance study of the conformation of bovine anaphylatoxin C5a in solution," <i>FEBS Lett.</i> 238(2), 289-294 (1988)			
74	Zhong G. <i>et al.</i> , "Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein" <i>Proc Natl Acad Sci USA</i> 94:13856-13861 (1997)			
75				
76				
77				
78				
79				
80				
Examiner: <i>Peter A. Ward</i>	Date Considered: 6/23/03			
EXAMINER: <i>Peter A. Ward</i>	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			